Kazakhstan's anti-cancer drug may be registered at the end of 2025

Kazakhstan's anti-cancer drug is currently undergoing second-level clinical trials. This was announced by Minister of Science and Higher Education Sayasat Nurbek at a briefing, reports the KazInform, a partner of TV BRICS.

According to him, Kazakhstan plans to register the drug by the end of 2025. Last year, the first level of clinical trials were completed – then researchers focused on colorectal cancer. Now the drug is being tested on all types of tumours. The Minister noted that the results of the trials already show positive dynamics.

"The response is good in many patients. As we said last year, the size of tumours decreased by 30 per cent on average, and remission has begun in those patients who participated in the testing of this drug according to a special procedure," Nurbek stressed.

Earlier it was reported that this summer Iran will unveil a cancer vaccine developed at the country's National Institute of Genetic Engineering and Biotechnology.

Photo: iStock